Viking Therapeutics Jumps on Early Weight-Loss Pill Results [BNN Bloomberg (Canada)]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: BNN Bloomberg
Patients in the study lost an average of 3.3% of their body weight in 28 days compared with a placebo and no serious adverse events were reported, Viking said in a statement. The shares rose as much as 21% in trading before US markets opened and have almost quadrupled in value this year through Monday's close. “Results are strong and we expect strong stock reaction today,” Joon Lee, a biotech analyst at Truist Securities, said in a note. Viking is one of a handful of companies, including market leaders Eli Lilly & Co. and Novo Nordisk A/S, racing to develop weight-loss drugs that can be taken by mouth rather than injected. The California biotech plans to move its medication, called VK2735, into mid-stage studies based on the results, according to the statement. Read More: Novo Nordisk's Obesity Pill Results Send Shares to Record Notably, there was a lower rate of stomach issues like diarrhea and vomiting among patients treated with Viking's drug compared to a placebo. Gastroi
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- A 3x Expected Rise In Mounjaro Sales Is Likely To Drive Eli Lilly's Q1 [Forbes]Forbes
- Global CDK 4/6 Inhibitor Drugs Market Outlook 2023-2035: A USD 66.63 Billion Market by 2035, Up From USD 9.03 Billion in 2022 [Yahoo! Finance]Yahoo! Finance
- Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics [Yahoo! Finance]Yahoo! Finance
- American Kidney Fund Launches National Kidney Health Equity Media Campaign [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk comes under Senate probe over pricing for weight loss drugs [Seeking Alpha]Seeking Alpha
LLY
Earnings
- 2/6/24 - Miss
LLY
Sec Filings
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- 4/16/24 - Form 4
- LLY's page on the SEC website